Protein Molecular Characteristics and Prognosis of Cervical Neuroendocrine Tumors

Cervical Cancer Clinical Trial

Official title:

Protein Molecular Characteristics and Prognosis of Cervical Neuroendocrine Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06276309
• Other study ID #: NECC2401
• Status: Recruiting
• Start date: February 1, 2024
• Est. completion date: June 30, 2024

Study information

• Verified date: February 2024
• Source: Fujian Maternity and Child Health Hospital
• Contact: Binhua Dong
• Phone: +86-0591-87558732
• Email: dongbinhua86[@]fjmu.edu.cn
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The clinical diagnosis and treatment data of 300 cases of cervical neuroendocrine tumors were collected, including age, preoperative biopsy pathology results, postoperative histopathological results, TCT results, and colposcopy biopsy pathology results. At the same time, paraffin tissue specimens (remaining specimens after pathological diagnosis) from 100 cases of cervical neuroendocrine tumors from multiple centers across the country were collected to establish a cervical neuroendocrine tumor data follow-up database. Protein concentration and omics analysis were performed on the data results, to evaluate the molecular characteristics and prognosis of cervical neuroendocrine tumor proteins, and to preliminarily explore its clinical application value.

Description:

1. The clinical diagnosis and treatment data of 300 cases of cervical neuroendocrine tumors were used for prognostic analysis.

(1) The diagnosis and treatment information of cervical neuroendocrine carcinoma in multiple hospitals was collected, including clinical and medical data such as age, preoperative HPV genotyping, preoperative biopsy pathological results, postoperative histopathological results, FIGO staging, prognosis and survival information, and follow-up of patients.

2. Protein and other omics analysis was performed on paraffin tissues of 100 cases of cervical neuroendocrine tumors Paraffin samples collected from 100 cases of cervical neuroendocrine tumors were identified, processed and segmtioned, and protein concentration and proteome were determined to establish the molecular characteristics and prognostic targets of cervical neuroendocrine tumors.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: June 30, 2024
• Est. primary completion date: June 30, 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Patients diagnosed with cervical neuroendocrine carcinoma by histopathology

2. Clinical data were complete

Exclusion Criteria:

1. Patients who are not being treated in our hospital

2. Patients with lack of follow-up data, unable to obtain survival information

3. Patients call to refuse to participate in this project

4. The quality of paraffin specimens can not meet the requirements of proteome concentration determination

Related Conditions & MeSH terms

• Cervical Cancer
• Cervical Lesion
• China
• Neuroendocrine Neoplasm
• Neuroendocrine Tumors
• Women

Locations

Country	Name	City	State
China	Xiangya Hospital, Central South University	Changsha	Hunan
China	Fujian Maternity and Child Health Hospital	Fuzhou	Fujian
China	Fujian Provincial Hospital	Fuzhou	Fujian
China	Jiangxi maternal and Child Health Hospital	Nanchang	Jiangxi
China	Ningde Mindong Hospital	Ningde	Fujian
China	Putian City first Hospital	Putian	Fujian
China	The Second Affiliated Hospital of Fujian Medical University	Quanzhou	Fujian
China	Maternal and Child Health Hospital of Hubei Province	Wuhan	Hubei
China	Zhangzhou affiliated Hospital of Fujian Medical University	Zhangzhou	Fujian

Sponsors (1)

Lead Sponsor	Collaborator
Fujian Maternity and Child Health Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	mortality rate	3-year mortality rate for cervical neuroendocrine carcinoma	Among patients with cervical neuroendocrine carcinoma, the mortality rate within 3 years following surgery
Primary	Disease-free survival	3-year disease-free survival for cervical neuroendocrine carcinoma	Among patients with cervical neuroendocrine carcinoma, the disease-free survival within 3 years following surgery